Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on $IOVA stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

$IOVA stock is up 3% today. Here's what we see in our data.  Quiver Quantitative

$IOVA stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges  Yahoo Finance

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO - simplywall.st

Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO  simplywall.st

Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO - simplywall.st

Click here to get full coverage on Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025]  Trefis

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Click here to get full coverage on Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience  Seeking Alpha

Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Click here to get full coverage on Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest

Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment  AInvest

Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs  MSN

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN

Click here to get full coverage on Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Nasdaq

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection  Nasdaq

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Nasdaq

Click here to get full coverage on Is This Beaten-Down Stock a Millionaire Maker? - The Motley Fool

Is This Beaten-Down Stock a Millionaire Maker?  The Motley Fool

Is This Beaten-Down Stock a Millionaire Maker? - The Motley Fool

Click here to get full coverage on Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade

Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks  StocksToTrade

Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade

Click here to get full coverage on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth  simplywall.st

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Click here to get full coverage on Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025]  Trefis

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Click here to get full coverage on Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ)  Seeking Alpha

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Click here to get full coverage on New Analyst Forecast: $IOVA Given $25.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IOVA Given $25.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IOVA Given $25.0 Price Target - Quiver Quantitative

Click here to get full coverage on Is Iovance Biotherapeutics Stock Due for a Big Rally? - Yahoo Finance

Is Iovance Biotherapeutics Stock Due for a Big Rally?  Yahoo Finance

Is Iovance Biotherapeutics Stock Due for a Big Rally? - Yahoo Finance

Click here to get full coverage on Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance

Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data  Yahoo Finance

Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance

Click here to get full coverage on Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest

Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization  AInvest

Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest

Click here to get full coverage on Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)  Yahoo Finance

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Click here to get full coverage on Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar

Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline  Morningstar

Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar

Click here to get full coverage on Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit  PR Newswire

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Click here to get full coverage on Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA - Finansavisen

Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA  Finansavisen

Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA - Finansavisen

Click here to get full coverage on Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA - Nasdaq

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA  Nasdaq

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA - Nasdaq

Click here to get full coverage on Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - Finansavisen

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm  Finansavisen

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - Finansavisen

Click here to get full coverage on Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView

Here’s why Iova stock surged 32% today and why the rally might not be over  TradingView

Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView

Click here to get full coverage on Is Iovance Biotherapeutics Stock Due for a Big Rally? - The Motley Fool

Is Iovance Biotherapeutics Stock Due for a Big Rally?  The Motley Fool

Is Iovance Biotherapeutics Stock Due for a Big Rally? - The Motley Fool

Click here to get full coverage on DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of - GlobeNewswire

DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of  GlobeNewswire

DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of - GlobeNewswire

Click here to get full coverage on Iovance (IOVA.O) Surges 28.43%: Unpacking the Drivers Behind the Intraday Rally - AInvest

Iovance (IOVA.O) Surges 28.43%: Unpacking the Drivers Behind the Intraday Rally  AInvest

Iovance (IOVA.O) Surges 28.43%: Unpacking the Drivers Behind the Intraday Rally - AInvest

Click here to get full coverage on Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Yahoo Finance

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer  Yahoo Finance

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Yahoo Finance

Click here to get full coverage on IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL,  GlobeNewswire

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

Click here to get full coverage on IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire

IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance  GlobeNewswire

IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire

Click here to get full coverage on Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)  The Globe and Mail

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Click here to get full coverage on IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop - GlobeNewswire

IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop  GlobeNewswire

IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop - GlobeNewswire

Click here to get full coverage on IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C.  GlobeNewswire

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Click here to get full coverage on This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - The Motley Fool

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?  The Motley Fool

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - The Motley Fool

Click here to get full coverage on Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA)  Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Click here to get full coverage on Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com

Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges  timothysykes.com

Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com

Click here to get full coverage on Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit  Morningstar

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar

Click here to get full coverage on IOVA Lawsuit Alert! Class Action Lawsuit Against Iovance Biotherapeutics - TipRanks

IOVA Lawsuit Alert! Class Action Lawsuit Against Iovance Biotherapeutics  TipRanks

IOVA Lawsuit Alert! Class Action Lawsuit Against Iovance Biotherapeutics - TipRanks

Click here to get full coverage on A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $1 to $20 - 富途牛牛

A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $1 to $20  富途牛牛

A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $1 to $20 - 富途牛牛

Click here to get full coverage on IOVA SECURITIES: Lose Money on Iovance Biotherapeutics - GlobeNewswire

IOVA SECURITIES: Lose Money on Iovance Biotherapeutics  GlobeNewswire

IOVA SECURITIES: Lose Money on Iovance Biotherapeutics - GlobeNewswire

Click here to get full coverage on Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy - Yahoo Finance

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy  Yahoo Finance

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy - Yahoo Finance

Click here to get full coverage on 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MarketBeat

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking  MarketBeat

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MarketBeat

Click here to get full coverage on Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire

Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman  GlobeNewswire

Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire

Click here to get full coverage on IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC  GlobeNewswire

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Click here to get full coverage on Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Finansavisen

Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class Action - IOVA  Finansavisen

Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Finansavisen

Click here to get full coverage on The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders - Finansavisen

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders  Finansavisen

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders - Finansavisen

Click here to get full coverage on IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance - GlobeNewswire

IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance  GlobeNewswire

IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance - GlobeNewswire

Click here to get full coverage on IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - TradingView

IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA  TradingView

IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - TradingView

Click here to get full coverage on IOVA LAWSUIT ALERT: The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Finansavisen

IOVA LAWSUIT ALERT: The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline  Finansavisen

IOVA LAWSUIT ALERT: The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Finansavisen

Click here to get full coverage on Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire

Investors who lost money on Iovance Biotherapeutics, Inc.  GlobeNewswire

Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire

Click here to get full coverage on Shareholders that lost money on Iovance Biotherapeutics, - GlobeNewswire

Shareholders that lost money on Iovance Biotherapeutics,  GlobeNewswire

Shareholders that lost money on Iovance Biotherapeutics, - GlobeNewswire

Click here to get full coverage on The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA - Finansavisen

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA  Finansavisen

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA - Finansavisen

Click here to get full coverage on Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) - GlobeNewswire

Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA)  GlobeNewswire

Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) - GlobeNewswire

Click here to get full coverage on Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join - GlobeNewswire

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join  GlobeNewswire

Iovance Biotherapeutics Inc (IOVA)

Price Chart

Key Statistics

Technicals

About IOVA

Latest News

$IOVA stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO - simplywall.st

Advanced Charts

Top Gainers

Top Losers